9. OraSure Technologies Inc. (NASDAQ:OSUR)
OraSure Technologies, Inc. (NASDAQ: OSUR) ranks No. 9 as a medical-diagnostics turnaround rather than a conventional high-growth stock. The company develops diagnostic tests and specimen-collection products used in infectious-disease testing, molecular research, genomics, and public-health programs, giving it an established operating platform despite its relatively modest market valuation.
Second-quarter 2026 revenue reached $30.6 million, increasing approximately 10% sequentially but declining around 2% year over year. Diagnostics revenue increased 1% to $19.4 million, supported by higher syphilis-testing revenue and Sickle SCAN sales, while Sample Management Solutions generated approximately $9.9 million. OraSure Technologies, Inc. (NASDAQ: OSUR) reported net income of approximately $6.2 million, although the result benefited materially from a noncash reduction in acquisition-related contingent consideration.
The company’s approximately $160.6 million in cash and investments provides time to introduce new products, improve margins, and consider strategic alternatives. Activist investors have also pushed for a potential sale, but an acquisition should not be treated as guaranteed. OraSure Technologies, Inc. (NASDAQ: OSUR) could rerate if revenue stabilizes and sustainable profitability emerges, although it remains a high-risk turnaround until those improvements become visible.
